Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683187 · ClinicalTrials.gov registry record · Phase 1
DPP4 Inhibition & Beta Cell Function
A Phase 1 study, sponsored by David D'Alessio, M.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02683187 is a Phase 1 study that has completed, run by David D'Alessio, M.D.. The registered enrollment target is 40 participants.
The verdict
NCT02683187, a Phase 1 study, has completed, sponsored by David D'Alessio, M.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is being done to determine the role of a hormone, glucagon-like peptide 1 (GLP-1), on insulin secretion and to study how GLP-1 works in in diabetic individuals as compared to non-diabetic individuals, under fasting conditions. GLP-1 is a naturally occurring hormone made in the intestines. It is released into the circulating blood after eating and helps to control the blood glucose levels by increasing insulin secretion by cells in the pancreas. However, the exact method by which GLP-1 causes insulin secretion and how GLP-1 activity is changed in diabetic persons remain unclear. This research is being done to address these questions and better understand the function of GLP-1. In this research, the investigators will use a synthetic form of Exendin-9 to determine the effects of GLP-1 on insulin secretion in diabetic and non-diabetic persons. Exendin-9 acts as a blocker of GLP-1 action, allowing us to study the specific effects of the GLP-1 hormone. Exendin-9 is an investigational compound, which means it is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA). In this study, the investigators will also use the drug Sitagliptin, which is an FDA-approved drug for the treatment of type 2 diabetes mellitus. In this study, use of Sitagliptin is considered investigational since it is not being used for treatment of diabetes but is instead being used to understand how GLP-1 works and to better understand how medications like Sitagliptin work in patients with type 2 diabetes mellitus.
Interventions
- DRUG Active Comparator: Sitagliptin
- DRUG Placebo Comparator - No Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683187
The ClinicalTrials.gov registry entry for NCT02683187 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David D'Alessio, M.D., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active Comparator: Sitagliptin is the first listed.
NCT02683187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683187 about?
NCT02683187 is a clinical study titled "DPP4 Inhibition & Beta Cell Function". This study is being done to determine the role of a hormone, glucagon-like peptide 1 (GLP-1), on insulin secretion and to study how GLP-1 works in in diabetic individuals as compared to non-diabetic individuals, under fasting conditions. GLP-1 is a naturally occurring hormone made in the intestines...
What is the current status of trial NCT02683187?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-03-01. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT02683187?
The interventions under investigation include: Active Comparator: Sitagliptin (DRUG), Placebo Comparator - No Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT02683187?
This trial is sponsored by David D'Alessio, M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.